Read + Share
Nishiyama N, Kita Y, Ito K, Kato M, et al. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in
Treatment Outcomes According to the Primary Site. Anticancer Res 2023;43:5041-5050.
PMID: 37909969
|
 |
|
Nishiyama N, Kita Y, Ito K, Kato M, et al. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in
Treatment Outcomes According to the Primary Site. Anticancer Res 2023;43:5041-5050.
PMID: 37909969
|
|
|
|